Clinical Trials Logo

Select Advanced Solid Tumors clinical trials

View clinical trials related to Select Advanced Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06402201 Recruiting - Clinical trials for Select Advanced Solid Tumors

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.

NCT ID: NCT04262466 Recruiting - Clinical trials for Select Advanced Solid Tumors

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Start date: February 25, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.